enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Enfortumab vedotin - Wikipedia

   en.wikipedia.org/wiki/Enfortumab_vedotin

   Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer. [4] [7] It is a nectin-4-directed antibody and microtubule inhibitor conjugate. [4] [7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. [5]

3. List of drugs granted breakthrough therapy designation

   en.wikipedia.org/wiki/List_of_drugs_granted...

   Enfortumab vedotin: Iptacopan: To treat paroxysmal nocturnal hemoglobinuria [4] Ivosidenib: Lecanemab: To treat Alzheimer's disease [4] Miglustat: Nedosiran: To lower urinary oxalate levels in primary hyperoxaluria type 1 and relatively preserved kidney function [4] Nirogacestat: To treat desmoid tumors [4] Pembrolizumab: Sutimlimab: Talquetamab

4. Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

   www.aol.com/news/seattle-genetics-enfortumab...

   The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

5. Monomethyl auristatin E - Wikipedia

   en.wikipedia.org/wiki/Monomethyl_auristatin_E

   Monomethyl auristatin E is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin.The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the antimitotic mechanism.

6. Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA ... - AOL

   www.aol.com/news/seagens-sgen-maa-enfortumab...

   The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.

7. Enavatuzumab - Wikipedia

   en.wikipedia.org/wiki/Enavatuzumab

   This monoclonal antibody –related article is a stub. You can help Wikipedia by expanding it.

8. Pinatuzumab vedotin - Wikipedia

   en.wikipedia.org/wiki/Pinatuzumab_vedotin

   Pinatuzumab vedotin (INN; [1] development codes DCDT2980S and FCU2703) is a monoclonal antibody designed for the treatment of B-cell malignancies. [ 2 ] This drug was developed by Genentech / Roche .

9. Erdafitinib - Wikipedia

   en.wikipedia.org/wiki/Erdafitinib

   [7] [14] The overall response rate in these adults was 32.2%, with 2.3% having a complete response and almost 30% having a partial response. [7] The response lasted for a median of approximately five-and-a-half months. [7] The trial was conducted in Asia, Europe, and the United States. [14] Erdafitinib received an accelerated approval. [7]